Scarica l'app Stockscreener
8.54
1.43%
0.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Longview News-Journal
How the (ATRA) price action is used to our Advantage - Stock Traders Daily
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2025-02-10 | Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 - BioSpace
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - Markets Insider
2025-02-09 | Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Brokerages - Armenian Reporter
Atara Biotherapeutics (NASDAQ:ATRA) Stock Quotes, Forecast and News Summary - Benzinga
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - Markets Insider
Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - Markets Insider
Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Price Target at $17.75 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - Markets Insider
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Wolf Haldenstein Adler Freeman & Herz LLP announces that it - GlobeNewswire
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for - EIN News
2025-02-03 | Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
2025-02-02 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
2025-01-31 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
HC Wainwright Issues Positive Outlook for ATRA Earnings - Defense World
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - GlobeNewswire Inc.
(ATRA) Investment Analysis - Stock Traders Daily
2025-01-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing
HC Wainwright Reaffirms Neutral Rating for Atara Biotherapeutics (NASDAQ:ATRA) - Defense World
Q3 EPS Forecast for Atara Biotherapeutics Lifted by Analyst - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out - Markets Insider
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - PR Newswire
Atara stock holds Neutral rating after workforce cut - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out - Markets Insider
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - The Malaysian Reserve
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect - Markets Insider
Atara reduction in workforce to impact 50% of current employees - MSN
2025-01-27 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect | NDAQ:ATRA | Press Release - Stockhouse Publishing
Atara Biotherapeutics Sees Its Share Price Fall - San Fernando Valley Business Journal
Atara to cut 50% of workforce amid FDA woes - MSN
Atara to cut 50% of workforce amid FDA woes (ATRA:NASDAQ) - Seeking Alpha
Atara Biotherapeutics’ (ATRA) “Neutral” Rating Reiterated at HC Wainwright - Defense World
What is HC Wainwright’s Forecast for ATRA FY2024 Earnings? - Defense World
Stifel cuts Atara Biotherapeutics target to $5, holds rating - MSN
Atara Biotherapeutics (NASDAQ:ATRA) Cut to Hold at RODMAN&RENSHAW - Defense World
Atara extends losses after FDA clinical hold - MSN
Clinical hold follows CRL for Atara - The Pharma Letter
Atara Biotherapeutics stock hits 52-week low at $6.4 amid challenges - Investing.com
Atara, Already Slapped With CRL, Gets A Clinical Hold As Well - News & Insights
Stifel cuts Atara Biotherapeutics target to $5, holds rating By Investing.com - Investing.com UK
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs - AOL
0.33%
4.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):